| |
When the world is changing, you need a global CDMO with a strong global presence to protect your molecule. Our team of experts help progress any molecule type, however complex, from pre-clinical to commercial.
Learn more about our tech transfer capabilities. 
|
|
Today’s Big NewsSep 19, 2024 |
|
Tuesday, September 24, 2024 | 2pm ET / 11am PT The transition from clinical to commercial supply chains is a pivotal challenge for life sciences organizations today. Join us for this important and timely discussion with industry experts for a deep dive into the scaling of logistics operations, and how to successfully navigate the complexities. Register now. 
|
|
| By Gabrielle Masson GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 million for its “plug-and-play” tech developed in the lab of—and with cells from—George Church, Ph.D. |
|
|
|
By Conor Hale The case is one of several intellectual property disputes between the medtech giant and Axonics—which is currently waiting to become a subsidiary of Boston Scientific. |
By Fraiser Kansteiner Earlier this month, Granules was slapped with a Form 483 following an inspection of its Telangana facility in India that ran from Aug. 26 to Sept. 6. The FDA’s report cites six observations around poor quality control procedures, subpar cleaning, cross-contamination risks and more. |
By Nick Paul Taylor Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 trial that missed its primary endpoint. The biotech came out swinging after the blow, accusing the FDA of sending a complete response letter that generally disregarded the evidence. |
|
Thursday, September 25, 2024 |11am ET / 8am PT In the fast-evolving field of cell and gene therapy, overcoming bottlenecks at every stage of the process is crucial. Join us to learn about best practices, innovative solutions, and strategies to enhance efficiency in cell and gene therapy manufacturing, management, and delivery. Register now. 
|
|
By Joseph Keenan Gavi, the Vaccine Alliance and the U.K. government ordered a combined 650,000 doses of Bavarian Nordic’s Jynneos mpox vaccine just days after the Danish drugmaker announced it would focus its resources to produce as many as 2 million doses by the end of 2024. |
By Gabrielle Masson Aligos Therapeutics is heralding a midstage win in metabolic-dysfunction associated steatohepatitis after three different doses of its drug candidate significantly slashed liver fat at 12 weeks. Despite the company's enthusiasm, the results failed to impress investors. |
By Ben Adams The Deerfield life sciences agency has bolstered its comms and marketing team with two new senior hires. |
By Nick Paul Taylor Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, looking into deals with groups working on other modalities and preparing to lay off staff. |
By Kevin Dunleavy A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migraines than a previous class of medicines. |
By Andrea Park In a bid to break down barriers facing both pharmas and payers in the life sciences industry, AscellaHealth has begun producing a new podcast that’ll talk through major issues in the space. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "Podnosis," we're diving into the healthcare topics employers are watching most closely. |
|
|---|
|
|
|
Who’s Leading the Way in Clinical Research? Nominate Them for the CRO Awards! The Fierce CRO Awards shine a spotlight on the organizations that are setting new standards in clinical research and development. If your CRO excels in innovation, quality, and leadership, it’s time to get the recognition you deserve. Submissions close October 3rd. SUBMIT NOW 
|
|
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
